{
    "clinical_study": {
        "@rank": "166324", 
        "arm_group": [
            {
                "arm_group_label": "0.2 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "PRX-102 0.2 mg/kg every 2 weeks"
            }, 
            {
                "arm_group_label": "1 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "PRX-102 1 mg/kg every 2 weeks"
            }, 
            {
                "arm_group_label": "2 mg/kg", 
                "arm_group_type": "Experimental", 
                "description": "PRX-102 2 mg/kg every 2 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This is the first human treatment with PRX-102, an enzyme being developed as a long-term\n      enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (alpha\n      galactosidase deficiency). The safety, tolerability, and exploratory efficacy will be\n      evaluated in this study of increasing doses.  Patients will be treated with infusions every\n      two weeks for 12 weeks (7 infusions)."
        }, 
        "brief_title": "Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Fabry Disease", 
        "condition_browse": {
            "mesh_term": "Fabry Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Symptomatic adult Fabry patients (\u226518 yrs)\n\n          -  Males: plasma and/or leucocyte alpha galactosidase activity (by activity assay) less\n             than lower limit of normal (LLN in plasma=3.2 nmol/hr/ml, LLN in leucocytes=32\n             nmol/hr/mg/protein)\n\n          -  Females: historical genetic test results consistent with Fabry mutations\n\n          -  Globotriaosylceramide (Gb3) concentration in urine > 1.5 times upper normal limit\n\n          -  Patients who have never received enzyme replacement therapy (ERT) in the past, or\n             patients who have not received ERT in the past 6 months and have a negative anti\n             alpha galactosidase antibody test\n\n          -  Chronic kidney disease - stages 1 or 2 (CKD1 or 2) (Appendix 7) with proteinuria >\n             200 mg/g protein-to-creatinine ratio or equivalent, measured in a Spot urine sample,\n             demonstrated in at least one of 2 separate samples (1 sample at screening visit and\n             the other from historical data)\n\n          -  The patient signs informed consent\n\n          -  Female patients and male patients whose co-partners are of child-bearing potential\n             agree to use a medically acceptable method of contraception, not including the rhythm\n             method\n\n        Exclusion Criteria:\n\n          -  Participation in any trial of an investigational drug within 30  days prior to study\n             screening\n\n          -  Chronic kidney disease stages 3-5 (CKD 3-5) (Appendix 7)\n\n          -  History of dialysis or renal transplantation\n\n          -  Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)\n             therapy initiated or dose changed in the 4 weeks prior to screening\n\n          -  Severe myocardial fibrosis by MRI (\u22652 late-enhancement [LE] positive left ventricular\n             segments) (Weidemann et al. 2009)\n\n          -  History of clinical stroke\n\n          -  Pregnant or nursing\n\n          -  Presence of HIV and/or HBsAg and/or Hepatitis C infections\n\n          -  Known allergies to ERT\n\n          -  Known allergy to Gadolinium based contrast agents\n\n          -  Presence of any medical, emotional, behavioral or psychological condition that, in\n             the judgment of the Investigator and/or Medical Director, would interfere with the\n             patient's compliance with the requirements of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01678898", 
            "org_study_id": "PB-102-F01"
        }, 
        "intervention": {
            "arm_group_label": [
                "0.2 mg/kg", 
                "1 mg/kg", 
                "2 mg/kg"
            ], 
            "intervention_name": "PRX-102", 
            "intervention_type": "Drug", 
            "other_name": "plant cell expressed recombinant human alpha-galactosidase-A"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Fabry disease", 
            "Alpha galactosidase deficiency", 
            "Metabolic storage disease"
        ], 
        "lastchanged_date": "April 4, 2014", 
        "location": [
            {
                "contact": {
                    "email": "dawn.laney@emory.edu", 
                    "last_name": "Dawn Jacob Laney", 
                    "phone": "404-778-8518"
                }, 
                "facility": {
                    "address": {
                        "city": "Atlanta", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30322"
                    }, 
                    "name": "Department of Human Genetics, Emory University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Jeannie Visootsak, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "scopeland2@kumc.edu", 
                    "last_name": "Sheri Copeland", 
                    "phone": "913-588-7691"
                }, 
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66160"
                    }, 
                    "name": "University of Kansas Medical Center"
                }, 
                "investigator": {
                    "last_name": "Ahmad Mahdi Tuffaha, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "kpusate1@jhmi.edu", 
                    "last_name": "Kristen L Pusateri", 
                    "phone": "443-287-7124"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21205"
                    }, 
                    "name": "Johns Hopkins University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Gustavo HB Maegawa, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "michelle.canfield@duke.edu", 
                    "last_name": "Michelle Canfield, RN MSN", 
                    "phone": "919-668-2195"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Marie McDonald, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Caren.Swift@baylorhealth.edu", 
                    "last_name": "Caren Swift", 
                    "phone": "214-820-4857"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75226"
                    }, 
                    "name": "Research Baylor Institute of Metabolic Disease"
                }, 
                "investigator": {
                    "last_name": "Raphael Schiffmann, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ttaber@oandoalpan.com", 
                    "last_name": "Tabitha Taber", 
                    "phone": "571-308-1906"
                }, 
                "facility": {
                    "address": {
                        "city": "Fairfax", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22030"
                    }, 
                    "name": "O & O Alpan LLC"
                }, 
                "investigator": {
                    "last_name": "Ozlem Goker Alpan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "donna.north@mh.org.au", 
                    "last_name": "Donna North", 
                    "phone": "613 9342 4219"
                }, 
                "facility": {
                    "address": {
                        "city": "Victoria", 
                        "country": "Australia", 
                        "zip": "3050"
                    }, 
                    "name": "Royal Melbourne Hospital"
                }, 
                "investigator": {
                    "last_name": "Kathy Nicholls, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gderlis@conexion.com.py", 
                    "last_name": "Derlis Emilio Gonzalez Rodriguez, MD", 
                    "phone": "595-21-423603"
                }, 
                "facility": {
                    "address": {
                        "city": "Asuncion", 
                        "country": "Paraguay"
                    }, 
                    "name": "Hematology and Clinical Research Private Institute"
                }, 
                "investigator": {
                    "last_name": "Derlis Emilio Gonzales Rodriguez, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rmgvdah@ucl.ac.uk", 
                    "last_name": "Derralynn Hughes, MD", 
                    "phone": "44 207 472 6588"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "NW3 2QG"
                    }, 
                    "name": "The Royal Free Hospital"
                }, 
                "investigator": {
                    "last_name": "Derralynn Hughes, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "Paraguay", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients", 
        "overall_official": {
            "affiliation": "Protalix", 
            "last_name": "Einat Almon, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Reportings of adverse events reported by the patient and from monitoring with clinical laboratory, physical examination and ECG", 
            "measure": "Adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01678898"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Gb3 concentrations in plasma and urine sediment", 
                "measure": "Gb3 concentrations", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Measurement of glomerular filtration and proteinuria", 
                "measure": "Kidney function", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "Short term brief pain inventory", 
                "measure": "Pain", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }
        ], 
        "source": "Protalix", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Protalix", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}